Publication:
miRNA-Based Therapies in B Cell Non-Hodgkin Lymphoma.

Simple item page
dc.contributor.authorFuertes, Teresa
dc.contributor.authorRamiro, Almudena R
dc.contributor.authorde Yebenes, Virginia G
dc.contributor.funderMinisterio de Ciencia, Innovación y Universidades (España)
dc.contributor.funderCentro Nacional de Investigaciones Cardiovasculares Carlos III (España)
dc.contributor.funderComplutense University of Madrid (España)
dc.contributor.funderInstituto de Salud Carlos III
dc.contributor.funderFundación ProCNIC
dc.date.accessioned2020-10-27T13:49:14Z
dc.date.available2020-10-27T13:49:14Z
dc.date.issued2020-10
dc.description.abstractNon-Hodgkin lymphoma (NHL) is a diverse class of hematological cancers, many of which arise from germinal center (GC)-experienced B cells. Thus GCs, the sites of antibody affinity maturation triggered during immune responses, also provide an environment that facilitates B cell oncogenic transformation. miRNAs provide attractive and mechanistically different strategies to treat these malignancies based on their potential for simultaneous modulation of multiple targets. Here, we discuss the scientific rationale for miRNA-based therapeutics in B cell neoplasias and review recent advances that may help establish a basis for novel candidate miRNA-based therapies for B cell-NHL (B-NHL).es_ES
dc.description.peerreviewedSíes_ES
dc.description.sponsorshipT.F. is supported by a PhD fellowship from the Spanish Ministerio de Ciencia, Innovacion y Universidades (BES-2017-079759), A.R.R. by CNIC funding, and V.G.d.Y. by the AECC foundation (INVES18013GARC) and by the Universidad Complutense de Madrid. This work was funded by Spanish Ministerio de Ciencia e Innovación (PID2019-107551RB-I00) and Spanish Ministerio de Ciencia, Innovacion y Universidades (SAF2016-75511-R) programs. The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the Ministerio de Ciencia e Innovación (MCIN), and the Pro CNIC Foundation and is a Severo Ochoa Center of Excellence (SEV-2015-0505). One European Patent Application titled ‘miRNA compositions for the treatment of mature B cell neoplasms’ EP16722679, EP17382740 was filed on March 3 2017.es_ES
dc.format.number10es_ES
dc.format.page932-947es_ES
dc.format.volume41es_ES
dc.identifier.citationTrends Immunol. 2020; 41(10):932-947es_ES
dc.identifier.doi10.1016/j.it.2020.08.006es_ES
dc.identifier.issn1471-4906
dc.identifier.journalTrends in immunologyes_ES
dc.identifier.pubmedID32888820es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/11209
dc.language.isoenges_ES
dc.publisherCell Presses_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/SEV-2015-0505es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/BES-2017-079759es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PID2019-107551RB-I00es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/SAF2016-75511-Res_ES
dc.relation.publisherversionhttps://doi.org/10.1016/j.it.2020.08.006es_ES
dc.repisalud.institucionCNICes_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Biología de linfocitos Bes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titlemiRNA-Based Therapies in B Cell Non-Hodgkin Lymphoma.es_ES
dc.typejournal articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublicationf254ab65-3359-496a-8c9c-bbd831a75fb7
relation.isAuthorOfPublicationff88956c-1343-4df1-8607-ffe91d34b37b
relation.isAuthorOfPublication.latestForDiscoveryf254ab65-3359-496a-8c9c-bbd831a75fb7

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
miRNA-BasedTherapiesBCell_2020.pdf
Size:
1.4 MB
Format:
Adobe Portable Document Format
Description:
Artículo
Download

Collections

Grupos de investigación